Sarepta Therapeutics (SRPT) Defended at Cantor Fitzgerald
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- S&P 500 up, Nasdaq at record high as megacap tech stocks rise
- Oil slips on rise in Middle East crude exports and G7 stocks release
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- Schneider Electric to acquire PTC for $22.6 billion in all-cash deal
- Five things to watch in markets in the week ahead
Tweet
Share
E-mail
Get Alerts SRPT Hot Sheet
Price: $17.48 -0.11%
Rating Summary:
19 Buy, 18 Hold, 6 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 17 | New: 26
Rating Summary:
19 Buy, 18 Hold, 6 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 17 | New: 26
Join SI Premium – FREE
Cantor Fitzgerald analyst Alethia Young is reiterating their conviction on Sarepta Therapeutics (NASDAQ: SRPT) amid today's weakness.
The firm reiterated an Overweight rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Amgen (AMGN) Reiterated at Neutral by Cantor Fitzgerald
- S&P Global (SPGI) PT Lowered to $531 at Mizuho
- SBA Communications (SBAC) PT Raised to $271 at Raymond James
Create E-mail Alert Related Categories
Analyst Comments, Trader TalkRelated Entities
Cantor Fitzgerald, Alethia YoungSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
